Pfizer (NYSE:PFE) Stock Acquired Rep. Laurel M. Lee

Representative Laurel M. Lee (R-Florida) recently bought shares of Pfizer Inc. (NYSE:PFE). In a filing disclosed on November 21st, the Representative disclosed that they had bought between $15,001 and $50,000 in Pfizer stock on October 21st.

Representative Laurel M. Lee also recently made the following trade(s):

• Sold $15,001 – $50,000 in shares of GE Vernova (NYSE:GEV) on 11/8/2024.
• Purchased $15,001 – $50,000 in shares of Apple (NASDAQ:AAPL) on 10/7/2024.
• Purchased $50,001 – $100,000 in shares of JPMorgan Chase & Co. (NYSE:JPM) on 9/10/2024.

Pfizer Price Performance

Shares of Pfizer stock opened at $25.65 on Friday. The stock’s fifty day moving average is $28.21 and its 200 day moving average is $28.57. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The stock has a market cap of $145.36 billion, a P/E ratio of 34.66, a P/E/G ratio of 0.80 and a beta of 0.67.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, topping the consensus estimate of $0.64 by $0.42. The firm had revenue of $17.70 billion for the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The business’s revenue for the quarter was up 31.2% compared to the same quarter last year. During the same quarter last year, the company earned ($0.17) earnings per share. Sell-side analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be paid a $0.42 dividend. The ex-dividend date of this dividend is Friday, November 8th. This represents a $1.68 annualized dividend and a dividend yield of 6.55%. Pfizer’s dividend payout ratio (DPR) is 227.03%.

Insider Buying and Selling

In related news, Director Scott Gottlieb acquired 1,000 shares of the stock in a transaction on Wednesday, October 30th. The stock was bought at an average cost of $28.24 per share, with a total value of $28,240.00. Following the transaction, the director now directly owns 10,000 shares in the company, valued at approximately $282,400. This represents a 11.11 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. 0.06% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Pfizer

Several institutional investors have recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. purchased a new position in Pfizer during the first quarter worth $315,000. Edgestream Partners L.P. bought a new stake in Pfizer in the first quarter worth about $243,000. EP Wealth Advisors LLC boosted its position in shares of Pfizer by 0.9% during the first quarter. EP Wealth Advisors LLC now owns 336,062 shares of the biopharmaceutical company’s stock valued at $9,326,000 after buying an additional 2,864 shares during the period. Stonebridge Capital Advisors LLC grew its stake in shares of Pfizer by 35.2% during the first quarter. Stonebridge Capital Advisors LLC now owns 26,586 shares of the biopharmaceutical company’s stock valued at $738,000 after buying an additional 6,921 shares during the last quarter. Finally, Gamco Investors INC. ET AL raised its holdings in shares of Pfizer by 123.9% in the first quarter. Gamco Investors INC. ET AL now owns 533,251 shares of the biopharmaceutical company’s stock worth $14,798,000 after buying an additional 295,139 shares during the period. Institutional investors own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on PFE shares. Daiwa Capital Markets raised shares of Pfizer from a “neutral” rating to an “outperform” rating and increased their price objective for the stock from $28.00 to $34.00 in a research note on Wednesday, August 7th. Daiwa America raised Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Wells Fargo & Company upped their price objective on Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 31st. Sanford C. Bernstein started coverage on Pfizer in a research note on Thursday, October 17th. They set a “market perform” rating and a $32.00 target price on the stock. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research note on Wednesday, October 23rd. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, Pfizer currently has a consensus rating of “Moderate Buy” and an average price target of $32.92.

About Representative Lee

Laurel Lee (Republican Party) is a member of the U.S. House, representing Florida’s 15th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2025. Lee (Republican Party) is running for re-election to the U.S. House to represent Florida’s 15th Congressional District. She declared candidacy for the Republican primary scheduled on August 20, 2024. Gov. Ron DeSantis (R) appointed Lee to serve as the Florida Secretary of State on January 28, 2019, after the resignation of Michael Ertel on January 24. Lee resigned on May 16, 2022. Lee was a judge of the 13th Judicial Circuit Court in Florida from 2013 to 2019. She was appointed to the court by Gov. Rick Scott (R) in May 2013. She was elected to the position in 2014. Laurel Lee earned undergraduate and law degrees from the University of Florida. Lee’s career experience includes working as an attorney with Carlton Fields, P.A., an assistant federal public defender and assistant U.S. attorney with the United States District Court for the Middle District of Florida, and a law clerk to James S. Moody on the United States District Court for the Middle District of Florida.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.